Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic DMARDs in psoriasis and psoriatic arthritis: a 15-year multicenter cohort study

Supplementary data of study entitled Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic DMARDs in psoriasis and psoriatic arthritis: a 15-year multicenter cohort study

Supplementary Fig 1. Kaplan-Meier curves showing the probability of HBV reactivation in patients with psoriasis, stratified by risk factors
Supplementary Fig 2. Kaplan-Meier curves showing the probability of HCV reactivation in patients with psoriasis, stratified by HCV viral load at baseline
Supplementary Fig 3. Kaplan-Meier curves showing the sensitivity analysis of HBV reactivation risks for different subgroups.
Supplementary Fig 4. Kaplan-Meier curves showing the sensitivity analysis of HCV reactivation risks for different subgroups.

Supplementary Table I. Demographic features of the enrolled patients
Supplementary Table II. Pairwise comparisons of the risk of HBV reactivation between the chronic HBV infection, occult, and resolved HBV groups
Supplementary Table III. Crude incidence rate of HBV reactivation in patients with psoriasis, stratified by drug class
Supplementary Table IV. Cox proportional hazards analysis of factors associated with HBV reactivation in patients with psoriasis receiving biologics
Supplementary Table V. Pairwise comparisons of HBV reactivation risk across therapeutic classes
Supplementary Table VI. Pairwise comparisons of the time to HBV reactivation across therapeutic classes
Supplementary Table VII. Crude incidence rate of HCV reactivation in patients with psoriasis, stratified by drug class
Supplementary Table VIII. Cox proportional hazards analysis of factors associated with HCV reactivation in patients with psoriasis receiving biologics
Supplementary Table IX. Crude incidence rates of HBV reactivation in patients with psoriasis, stratified by drug class in the sensitivity analysis.
Supplementary Table X. Pairwise comparisons of HBV reactivation risk across therapeutic classes in the sensitivity analysis.
Supplementary Table XI. Cox proportional hazards analysis of factors associated with HBV reactivation in patients with psoriasis receiving biologics in the sensitivity analysis.
Supplementary Table XII. Crude incidence rate of HCV reactivation in patients with psoriasis, stratified by drug class in the sensitivity analysis.
Supplementary Table XIII. Cox proportional hazards analysis of factors associated with HCV reactivation in patients with psoriasis receiving biologics in the sensitivity analysis.